Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
83.18 CHF | +1.86% |
|
-.--% | +20.95% |
06-20 | Edwards Lifesciences Insider Sold Shares Worth $492,258, According to a Recent SEC Filing | MT |
06-17 | Edwards Lifesciences Corporation Announces Executive Changes | CI |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The opinion of analysts covering the stock has improved over the past four months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- With an expected P/E ratio at 34.47 and 29.32 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+20.95% | 54.88B | - | ||
+5.10% | 212B | B | ||
+10.16% | 188B | B- | ||
+30.73% | 157B | B- | ||
+33.51% | 114B | A- | ||
+3.54% | 64.01B | A- | ||
+1.63% | 48.83B | B+ | ||
-3.65% | 39.3B | A | ||
+1.93% | 35.97B | - | ||
+8.50% | 27B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- EW Stock
- 001065343 Stock
- Ratings Edwards Lifesciences Corporation